Aidence is a pioneering startup specializing in artificial intelligence (AI) solutions for the oncology pathway, particularly focusing on lung cancer diagnosis and management. The company has developed the Veye suite of medical imaging AI applications, which are designed to seamlessly integrate into existing radiology workflows. This suite includes Veye Lung Nodules, an automated lung nodule management assistant that aids radiologists in detecting and quantifying lung nodules on chest CT scans. The Veye applications are CE certified, ensuring they meet European health, safety, and environmental protection standards.

Aidence primarily serves healthcare providers, including hospitals and clinics, with a notable presence in the United Kingdom and the Netherlands. The company collaborates with prominent institutions such as the NHS England and has partnered with pharmaceutical giant AstraZeneca to support early lung cancer diagnosis using AI technology.

Operating in the medical imaging and healthcare technology market, Aidence employs a business-to-business (B2B) model. It generates revenue by licensing its AI applications to healthcare providers and institutions. These clients benefit from improved diagnostic accuracy and efficiency, which can lead to better patient outcomes and streamlined workflows.

Aidence's innovative approach combines deep learning algorithms with the expertise of clinical specialists to create solutions that are both effective and user-friendly. By integrating directly into Picture Archiving and Communication Systems (PACS), Aidence ensures that its tools are easily accessible to radiologists during their routine clinical practice and lung cancer screening programs.

In summary, Aidence is at the forefront of leveraging AI to enhance the oncology pathway, providing valuable tools to healthcare providers for early and accurate lung cancer diagnosis.

Keywords: AI, oncology, lung cancer, medical imaging, radiology, healthcare, deep learning, Veye suite, PACS integration, B2B.